Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinson's disease.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
05
2020
accepted:
27
07
2020
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
9
10
2020
Statut:
epublish
Résumé
A higher levodopa dose is a strong risk factor for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). However, levodopa dose can change during long-term medication. We explored the relationship between levodopa dose and time to onset of LID using longitudinal multicenter data. Medical records of 150 patients who were diagnosed with de novo PD and treated with levodopa until onset of LID were collected. Levodopa dose were assessed as the dose at 6 months from levodopa initiation and rate of dose increase between 6 months and onset of LID. The groups with earlier LID onset had higher levodopa and levodopa-equivalent dose at the first 6 months of treatment and rapid increase in both levodopa and levodopa-equivalent dose. Multivariable linear regression models revealed that female sex, severe motor symptom at levodopa initiation, and higher rate of increase in both levodopa and levodopa-equivalent dose were significantly associated with early onset of LID. The present results demonstrated that rapid increase in levodopa dose or levodopa-equivalent dose is associated with early onset of LID.
Identifiants
pubmed: 32817705
doi: 10.1371/journal.pone.0237472
pii: PONE-D-20-13495
pmc: PMC7444533
doi:
Substances chimiques
Antiparkinson Agents
0
Levodopa
46627O600J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237472Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arch Neurol. 2006 Dec;63(12):1756-60
pubmed: 17172616
Arch Neurol. 2006 Feb;63(2):205-9
pubmed: 16476808
N Engl J Med. 2000 May 18;342(20):1484-91
pubmed: 10816186
Clin Trials. 2005;2(6):509-18
pubmed: 16422311
J Neural Transm (Vienna). 2004 Apr;111(4):497-509
pubmed: 15057519
Mov Disord. 2001 May;16(3):448-58
pubmed: 11391738
Neurology. 2008 Aug 12;71(7):474-80
pubmed: 18579806
Clin Neuropharmacol. 2009 Nov-Dec;32(6):326-9
pubmed: 19855268
Mov Disord. 2013 Jul;28(8):1064-71
pubmed: 23630119
Ann Neurol. 2017 Nov;82(5):850-854
pubmed: 29059491
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Arch Neurol. 2004 Jul;61(7):1044-53
pubmed: 15262734
J Neurol. 1999 Dec;246(12):1127-33
pubmed: 10653303
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Neurology. 2016 Jan 19;86(3):231-40
pubmed: 26718573
Neurology. 2014 May 6;82(18):1597-604
pubmed: 24719485
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):423-431
pubmed: 29075830
Front Neurol. 2018 Dec 20;9:1133
pubmed: 30619078
JAMA. 2000 Oct 18;284(15):1931-8
pubmed: 11035889